# IBRX catalysts: ImmunityBio, Inc. PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/ibrx/catalysts

> ImmunityBio, Inc. (IBRX) has 20 upcoming catalysts. The next is the ImmunityBio, Inc. PDUFA date, January 6, 2027.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, exact day, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### What are the upcoming FDA catalysts for IBRX?

ImmunityBio, Inc. (IBRX) has 20 upcoming catalysts. The next is the ImmunityBio, Inc. PDUFA date, January 6, 2027. SEC Form 10-Q: "In addition, while we have pursued additional regulatory submissions in the first quarter of 2026, such as a refiling of our sBLA after a submission in 2025 for BCG-unresponsive NMIBC patients in the papillary indication for which we received a PDUFA target action date of January 6, 2027, and are pursuing and anticipating certain additional regulatory submissions in 2026 and beyond following ongoing discussions with the FDA and other international regulatory agencies, the regulatory review process is dynamic and highly uncertain." [Calendar and source filings](https://sec-api.dev/companies/ibrx/catalysts)

Source: SEC Form 10-Q, accession 0001326110-26-000079, https://www.sec.gov/Archives/edgar/data/1326110/000132611026000079/ibrx-20260630.htm (retrieved 2026-11-12). Last confirmed 2026-08-04. Cite: https://sec-api.dev/companies/ibrx/catalysts#answer

## Company

| Field | Value |
| --- | --- |
| Name | ImmunityBio, Inc. |
| Ticker | IBRX (Nasdaq) |
| SEC CIK | 1326110 |
| SIC | 2836 |
| SEC filings | https://sec-api.dev/companies/ibrx |

## Cash runway

Cash $334.3M as of 2026-09-30; quarterly burn $75.3M; about 13.3 months of runway at that rate (XBRL company facts, accession 0001326110-26-000099).

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| May 2022 | [ImmunityBio, Inc. complete response letter (CRL)](https://sec-api.dev/companies/ibrx/catalysts) | IBRX |  | completed, complete response letter | "FDA delivered a complete response letter ("CRL") to us regarding the BLA filed in May 2022, indicating that the FDA had determined that it could not approve the original BLA submission in its initial form, and the FDA made recommendations to address the issues raised." ([SEC prospectus (424B)](https://www.sec.gov/Archives/edgar/data/1326110/000119312525331242/d19212d424b5.htm)) |
| December 31, 2022 | [ImmunityBio, Inc. FDA approval](https://sec-api.dev/companies/ibrx/catalysts) | IBRX |  | completed, approved | "For example, the shareholder representative for the holders of regulatory milestone CVRs has notified us that it is exploring, and intends to pursue, claims on behalf of such holders based on our alleged failure to use commercially reasonable efforts to secure FDA approval of the BLA on or before the December 31, 2022 milestone date." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1326110/000132611025000139/ibrx-20250930.htm)) |
| May 2023 | [ImmunityBio, Inc. complete response letter (CRL)](https://sec-api.dev/companies/ibrx/catalysts) | IBRX |  | completed, complete response letter | "For example, we had previously hired sales and marketing personnel for a launch of our now-approved product, but we received a CRL from the FDA in May 2023." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1326110/000132611026000099/ibrx-20260930.htm)) |
| October 23, 2023 | [ImmunityBio, Inc. complete response letter (CRL)](https://sec-api.dev/companies/ibrx/catalysts) | IBRX |  | completed, complete response letter | "On October 23, 2023, we announced that we had completed the resubmission of the BLA addressing the issues in the CRL." ([SEC prospectus (424B)](https://www.sec.gov/Archives/edgar/data/1326110/000119312525331242/d19212d424b5.htm)) |
| October 26, 2023 | [ImmunityBio, Inc. NDA/BLA acceptance](https://sec-api.dev/companies/ibrx/catalysts) | IBRX |  | completed | "October 26, 2023, we announced that the FDA had accepted our BLA resubmission for review and considered it as a complete response to the CRL." ([SEC prospectus (424B)](https://www.sec.gov/Archives/edgar/data/1326110/000119312525331242/d19212d424b5.htm)) |
| April 22, 2024 | [ANKTIVA (inbakicept) FDA approval](https://sec-api.dev/pdufa/inbakicept) | IBRX |  | completed, approved | "On April 22, 2024, the FDA approved our product, ANKTIVA with bacillus Calmette-Guérin ("BCG") for the treatment of adult patients with BCG-unresponsive non-muscle invasive bladder cancer ("NMIBC") with carcinoma in situ ("CIS"), with or without papillary tumors (the "approved product")." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1326110/000119312524274438/d883742d8k.htm)) |
| April 23, 2024 | [ANKTIVA (inbakicept) PDUFA date](https://sec-api.dev/pdufa/inbakicept) | IBRX |  | completed, approved | "Although such designations may not lead to a faster development process or regulatory review and may not increase the likelihood that a product candidate will receive approval, N-803 (Anktiva), our lead biologic commercial product candidate, has received Breakthrough Therapy and Fast Track designations and is currently under review by the U.S. Food and Drug Administration (the FDA) for treatment in combination with bacillus Calmette-Guérin (BCG) of patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without Ta or T1 disease and has a new user fee goal date (PDUFA date) of April 23, 2024." ([SEC prospectus (424B)](https://www.sec.gov/Archives/edgar/data/1326110/000119312525165807/d941601d424b5.htm)) |
| April 23, 2024 | [ImmunityBio, Inc. PDUFA date](https://sec-api.dev/companies/ibrx/catalysts) | IBRX |  | scheduled | "The FDA has set a new user fee goal date (PDUFA date) of April 23, 2024." ([SEC prospectus (424B)](https://www.sec.gov/Archives/edgar/data/1326110/000119312525165807/d941601d424b5.htm)) |
| November 12, 2024 | [ImmunityBio, Inc. earnings report](https://sec-api.dev/companies/ibrx/catalysts) | IBRX |  | completed | "ImmunityBio Reports Third-Quarter 2024 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1326110/000132611024000109/ibrx-20241112x8kexhibit991.htm)) |
| Mar 2025 | [ANKTIVA (inbakicept) NDA/BLA submission](https://sec-api.dev/pdufa/inbakicept) | IBRX |  | completed | "In March 2025, the Company completed its submission to the FDA of the sBLA for the use of ANKTIVA plus BCG in BCG-unresponsive NMIBC in the papillary indication." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1326110/000119312525112057/d949868dex991.htm)) |
| March 3, 2025 | [ImmunityBio, Inc. earnings report](https://sec-api.dev/companies/ibrx/catalysts) | IBRX |  | completed | "ImmunityBio Reports Sales Momentum & Unit Growth Since Permanent J-code Issuance (J9028) in January 2025 and Financial Results for Year End 2024" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1326110/000132611025000031/ibrx-202533x8kexhibit991.htm)) |
| April 15, 2025 | [ImmunityBio, Inc. earnings report](https://sec-api.dev/companies/ibrx/catalysts) | IBRX |  | completed | "The amounts reported in this press release reflect the company's preliminary estimates based solely upon information available to it as of the date of this press release, and the amounts reported are not a comprehensive statement of its financial results or position as of March 31, 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1326110/000132611025000044/ibrx-20254158xkexhibit991.htm)) |
| May 12, 2025 | [ImmunityBio, Inc. earnings report](https://sec-api.dev/companies/ibrx/catalysts) | IBRX |  | completed | "CULVER CITY, Calif. — May 12, 2025 — ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced certain operational results following approval of the permanent J-code (J9028) in January 2025, as well as its financial results for the first-quarter ended March 31, 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1326110/000132611025000069/ibrx-2025512x8kexhibit991.htm)) |
| July 24, 2025 | [ImmunityBio, Inc. earnings report](https://sec-api.dev/companies/ibrx/catalysts) | IBRX |  | completed | "CULVER CITY, Calif.,  July 25, 2025  ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced preliminary financial results for the fiscal quarter ended June 30, 2025, and clinical progress across its pipeline." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1326110/000119312525164789/d20571dex991.htm)) |
| August 5, 2025 | [ImmunityBio, Inc. earnings report](https://sec-api.dev/companies/ibrx/catalysts) | IBRX |  | completed | "ImmunityBio Reports Operational and Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1326110/000132611025000112/ibrx-202585x8kexhibit991.htm)) |
| September 26, 2025 | [ANKTIVA (inbakicept) FDA approval](https://sec-api.dev/pdufa/inbakicept) | IBRX |  | completed, approved | "After SRS's motion for leave to amend was denied, on September 26, 2025, SRS sent the company a further notice of claims and essentially the same arbitration demand, asserting that the company had breached its obligations to exercise commercially reasonable efforts to achieve FDA approval of ANKTIVA on or before December 31, 2022." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1326110/000132611026000099/ibrx-20260930.htm)) |
| October 13, 2025 | [Nai + pembrolizumab primary completion](https://sec-api.dev/pdufa/nai-pembrolizumab) | IBRX | Non Small Cell Lung Cancer | withdrawn | "NCT03520686 (Nogapendekin Alfa Inbakicept for Advanced Non-Small Cell Lung Cancer): Overall Status TERMINATED; Phase PHASE3; Primary Completion 2025-10-13 (ACTUAL); Lead Sponsor ImmunityBio, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT03520686)) |
| October 13, 2025 | [N-803 primary completion](https://sec-api.dev/pdufa/n-803) | IBRX | Pancreatic Cancer | completed | "NCT04390399 (Combination Immunotherapy Plus Standard-of-Care Chemotherapy Versus Standard-of-Care Chemotherapy for the Treatment of Locally Advanced or Metastatic Pancreatic Cancer): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2025-10-13 (ACTUAL); Lead Sponsor ImmunityBio, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04390399)) |
| November 4, 2025 | [ImmunityBio, Inc. earnings report](https://sec-api.dev/companies/ibrx/catalysts) | IBRX |  | completed | "ImmunityBio Reports Operational and Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1326110/000132611025000138/ibrx-2025114x8kexhibit991.htm)) |
| January 15, 2026 | [ImmunityBio, Inc. earnings report](https://sec-api.dev/companies/ibrx/catalysts) | IBRX |  | completed | "CULVER CITY, Calif., Jan. 15, 2026 — ImmunityBio, Inc. (NASDAQ: IBRX), a vertically-integrated commercial stage biotechnology company, announced today preliminary select operational results for the fiscal quarter and full year ending December 31, 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1326110/000132611026000008/ibrx-20261158xkexhibit991.htm)) |
| April 9, 2026 | [ImmunityBio, Inc. earnings report](https://sec-api.dev/companies/ibrx/catalysts) | IBRX |  | completed | "CULVER CITY, Calif., Apr. 9, 2026 — ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage biotechnology company, announced today preliminary select operational results for the fiscal quarter ending March 31, 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1326110/000132611026000036/ibrx-2026498xkexhibit991.htm)) |
| August 4, 2026 | [ImmunityBio, Inc. earnings report](https://sec-api.dev/companies/ibrx/catalysts) | IBRX |  | completed | "August 4, 2026 — ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage biotechnology company, today announced financial and operational results for the second quarter ended June 30, 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1326110/000132611026000077/ibrx-202684x8kexhibit991.htm)) |
| Q4 2026 | [ANKTIVA (inbakicept) NDA/BLA submission](https://sec-api.dev/pdufa/inbakicept) | IBRX | BCG-naïve NMIBC | scheduled | "•BCG Naïve Primary Endpoint Met: In November 2026, we reported that the primary endpoint for Cohort A was met in the randomized QUILT-2.005 trial, and we remain on track to submit an sBLA to the FDA in the fourth quarter of 2026 for ANKTIVA in combination with BCG in patients with BCG-naïve NMIBC." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1326110/000132611026000097/ibrx-2026119x8kexhibit991.htm)) |
| October 2026 | [N-803 (il-15 superagonist) primary completion](https://sec-api.dev/pdufa/n-803-il-15-superagonist) | IBRX | Long COVID | delayed | "NCT07108036 (A Study to Assess Anktiva in Patients With Long Covid-19.): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2026-10 (ESTIMATED); Lead Sponsor ImmunityBio, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07108036)) |
| Oct 2026 to Jan 2027 | [N-803 (il-15 superagonist) topline data readout](https://sec-api.dev/pdufa/n-803-il-15-superagonist) | IBRX | Long COVID | scheduled | "NCT07108036 (A Study to Assess Anktiva in Patients With Long Covid-19.): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2026-10 (ESTIMATED); Lead Sponsor ImmunityBio, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07108036)) |
| October 14, 2026 | [ANKTIVA (inbakicept) label expansion decision](https://sec-api.dev/pdufa/inbakicept) | IBRX | BGC-unresponsive nonmuscle invasive bladder cancer | completed, approved | "•FDA Expanded Approval: On October 14, 2026, the U.S. Food and Drug Administration (FDA) approved our supplemental Biologics License Application (sBLA) expanding the approved indication for ANKTIVA® in combination with Bacillus Calmette-Guérin (BCG) to include adult patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC)." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1326110/000132611026000097/ibrx-2026119x8kexhibit991.htm)) |
| November 2026 | [N-803 and bcg primary completion](https://sec-api.dev/pdufa/n-803-and-bcg) | IBRX | Non-muscle Invasive Bladder Cancer (NMIBC) | scheduled | "NCT06829823 (Clinical Trial of Ablation Therapy in Participants With Intermediate-Risk Non-Muscle Invasive Papillary Bladder Cancer): Overall Status NOT_YET_RECRUITING; Phase PHASE2; Primary Completion 2026-11 (ESTIMATED); Lead Sponsor ImmunityBio, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06829823)) |
| Nov 2026 to Feb 2027 | [N-803 and bcg topline data readout](https://sec-api.dev/pdufa/n-803-and-bcg) | IBRX | Non-muscle Invasive Bladder Cancer (NMIBC) | scheduled | "NCT06829823 (Clinical Trial of Ablation Therapy in Participants With Intermediate-Risk Non-Muscle Invasive Papillary Bladder Cancer): Overall Status NOT_YET_RECRUITING; Phase PHASE2; Primary Completion 2026-11 (ESTIMATED); Lead Sponsor ImmunityBio, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06829823)) |
| November 9, 2026 | [ImmunityBio, Inc. earnings report](https://sec-api.dev/companies/ibrx/catalysts) | IBRX |  | completed | "November 9, 2026 — ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced continued global expansion, expanded FDA approval, and financial results for the third quarter ended September 30, 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1326110/000132611026000097/ibrx-2026119x8kexhibit991.htm)) |
| January 6, 2027 | [ImmunityBio, Inc. PDUFA date](https://sec-api.dev/companies/ibrx/catalysts) | IBRX |  | scheduled | "In addition, while we have pursued additional regulatory submissions in the first quarter of 2026, such as a refiling of our sBLA after a submission in 2025 for BCG-unresponsive NMIBC patients in the papillary indication for which we received a PDUFA target action date of January 6, 2027, and are pursuing and anticipating certain additional regulatory submissions in 2026 and beyond following ongoing discussions with the FDA and other international regulatory agencies, the regulatory review process is dynamic and highly uncertain." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1326110/000132611026000079/ibrx-20260630.htm)) |
| January 6, 2027 | [ANKTIVA (inbakicept) PDUFA date](https://sec-api.dev/pdufa/inbakicept) | IBRX |  | scheduled | "In May 2026, we announced the FDA accepted for review our sBLA for ANKTIVA indicated with BCG for the treatment of adult patients with BCG-unresponsive NMIBC with papillary tumors without CIS and assigned a PDUFA target action date of January 6, 2027." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1326110/000132611026000079/ibrx-20260630.htm)) |
| March 2027 | [Anktiva primary completion](https://sec-api.dev/pdufa/anktiva) | IBRX | Long COVID; Long COVID Syndrome; Long Covid 19 | scheduled | "NCT07123727 (A Study to Examine Anktiva for the Treatment of COVID-19.): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-03 (ESTIMATED); Lead Sponsor ImmunityBio, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07123727)) |
| Mar to Jun 2027 | [Anktiva topline data readout](https://sec-api.dev/pdufa/anktiva) | IBRX | Long COVID; Long COVID Syndrome; Long Covid 19 | scheduled | "NCT07123727 (A Study to Examine Anktiva for the Treatment of COVID-19.): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-03 (ESTIMATED); Lead Sponsor ImmunityBio, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07123727)) |
| May 2027 | [N-803 primary completion](https://sec-api.dev/pdufa/n-803) | IBRX | Platinum-resistant Ovarian Cancer | scheduled | "NCT06710288 (A Phase 2, Open-label, Single-arm Study Of Autologous M-CENK Adoptive Cell Therapy And N-803 (IL-15 Superagonist) In Combination With Gemcitabine In Participants With Recurrent Platinum-Resistant High-Grade Ovarian Cancer): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-05 (ESTIMATED); Lead Sponsor ImmunityBio, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06710288)) |
| May to Aug 2027 | [N-803 topline data readout](https://sec-api.dev/pdufa/n-803) | IBRX | Platinum-resistant Ovarian Cancer | scheduled | "NCT06710288 (A Phase 2, Open-label, Single-arm Study Of Autologous M-CENK Adoptive Cell Therapy And N-803 (IL-15 Superagonist) In Combination With Gemcitabine In Participants With Recurrent Platinum-Resistant High-Grade Ovarian Cancer): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-05 (ESTIMATED); Lead Sponsor ImmunityBio, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06710288)) |
| May to Aug 2027 | [Cd19 t-hank- iv administration topline data readout](https://sec-api.dev/pdufa/cd19-t-hank-iv-administration) | IBRX | Relapsed B-Cell Non Hodgkin Lymphoma | scheduled | "NCT07125872 (Study of Relapsed/ Refractory B-cell Non- Hodgkin Lymphoma): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-05-25 (ESTIMATED); Lead Sponsor ImmunityBio, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07125872)) |
| May 2027 | [Cd19 t-hank- iv administration primary completion](https://sec-api.dev/pdufa/cd19-t-hank-iv-administration) | IBRX | Relapsed B-Cell Non Hodgkin Lymphoma | scheduled | "NCT07125872 (Study of Relapsed/ Refractory B-cell Non- Hodgkin Lymphoma): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-05-25 (ESTIMATED); Lead Sponsor ImmunityBio, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07125872)) |
| Aug to Nov 2027 | [Nogapendekin alfa inbakicept (nai) topline data readout](https://sec-api.dev/pdufa/nogapendekin-alfa-inbakicept-nai) | IBRX | Sepsis; Septic Shock; Lymphopenia | scheduled | "NCT07578558 (NAI for Sepsis With Persistent Lymphopenia): Overall Status NOT_YET_RECRUITING; Phase PHASE2; Primary Completion 2027-08-03 (ESTIMATED); Lead Sponsor ImmunityBio, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07578558)) |
| August 2027 | [Nogapendekin alfa inbakicept (nai) primary completion](https://sec-api.dev/pdufa/nogapendekin-alfa-inbakicept-nai) | IBRX | Sepsis; Septic Shock; Lymphopenia | scheduled | "NCT07578558 (NAI for Sepsis With Persistent Lymphopenia): Overall Status NOT_YET_RECRUITING; Phase PHASE2; Primary Completion 2027-08-03 (ESTIMATED); Lead Sponsor ImmunityBio, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07578558)) |
| December 2027 | [N-803 primary completion](https://sec-api.dev/pdufa/n-803) | IBRX | Relapsed B-Cell Non-Hodgkin Lymphoma | scheduled | "NCT07477366 (Study of CD19 t-haNK and NAI With Rituximab in Participants With Indolent Non-Hodgkin Lymphoma): Overall Status NOT_YET_RECRUITING; Phase PHASE2; Primary Completion 2027-12 (ESTIMATED); Lead Sponsor ImmunityBio, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07477366)) |
| Dec 2027 to Mar 2028 | [N-803 topline data readout](https://sec-api.dev/pdufa/n-803) | IBRX | Relapsed B-Cell Non-Hodgkin Lymphoma | scheduled | "NCT07477366 (Study of CD19 t-haNK and NAI With Rituximab in Participants With Indolent Non-Hodgkin Lymphoma): Overall Status NOT_YET_RECRUITING; Phase PHASE2; Primary Completion 2027-12 (ESTIMATED); Lead Sponsor ImmunityBio, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07477366)) |
| May to Aug 2028 | [Nogapendekin alfa inbakicept (nai) topline data readout](https://sec-api.dev/pdufa/nogapendekin-alfa-inbakicept-nai) | IBRX | Sepsis | scheduled | "NCT07783789 (NAI Plus Standard of Care Compared With Placebo Plus Standard of Care in Critically Ill Adults With Sepsis): Overall Status NOT_YET_RECRUITING; Phase PHASE2; Primary Completion 2028-05-12 (ESTIMATED); Lead Sponsor ImmunityBio, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07783789)) |
| May 2028 | [Nogapendekin alfa inbakicept (nai) primary completion](https://sec-api.dev/pdufa/nogapendekin-alfa-inbakicept-nai) | IBRX | Sepsis | scheduled | "NCT07783789 (NAI Plus Standard of Care Compared With Placebo Plus Standard of Care in Critically Ill Adults With Sepsis): Overall Status NOT_YET_RECRUITING; Phase PHASE2; Primary Completion 2028-05-12 (ESTIMATED); Lead Sponsor ImmunityBio, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07783789)) |
| September 2028 | [N-803 primary completion](https://sec-api.dev/pdufa/n-803) | IBRX | NSCLC Stage IV | scheduled | "NCT06745908 (Clinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Monotherapy in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Acquired Resistance to Immune Checkpoint Inhibitor Therapy): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-09 (ESTIMATED); Lead Sponsor ImmunityBio, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06745908)) |
| Sep to Dec 2028 | [N-803 topline data readout](https://sec-api.dev/pdufa/n-803) | IBRX | NSCLC Stage IV | scheduled | "NCT06745908 (Clinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Monotherapy in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Acquired Resistance to Immune Checkpoint Inhibitor Therapy): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-09 (ESTIMATED); Lead Sponsor ImmunityBio, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06745908)) |
| Aug to Nov 2029 | [N-803 + pembrolizumab topline data readout](https://sec-api.dev/pdufa/n-803-pembrolizumab) | IBRX | Non-Small Cell Lung Cancer; Small Cell Lung Cancer; Urothelial Carcinoma | scheduled | "NCT03228667 (QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2029-08-31 (ESTIMATED); Lead Sponsor ImmunityBio, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT03228667)) |
| August 2029 | [N-803 + pembrolizumab primary completion](https://sec-api.dev/pdufa/n-803-pembrolizumab) | IBRX | Non-Small Cell Lung Cancer; Small Cell Lung Cancer; Urothelial Carcinoma | scheduled | "NCT03228667 (QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2029-08-31 (ESTIMATED); Lead Sponsor ImmunityBio, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT03228667)) |
| Dec 2029 to Mar 2030 | [Anktiva topline data readout](https://sec-api.dev/pdufa/anktiva) | IBRX | Glioblastoma | scheduled | "NCT06061809 (N-803 and PD-L1 t-haNK Combined With Bevacizumab for Recurrent or Progressive Glioblastoma): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2029-12-31 (ESTIMATED); Lead Sponsor ImmunityBio, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06061809)) |
| December 2029 | [Anktiva primary completion](https://sec-api.dev/pdufa/anktiva) | IBRX | Glioblastoma | scheduled | "NCT06061809 (N-803 and PD-L1 t-haNK Combined With Bevacizumab for Recurrent or Progressive Glioblastoma): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2029-12-31 (ESTIMATED); Lead Sponsor ImmunityBio, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06061809)) |

## Drugs

- [Anktiva](https://sec-api.dev/pdufa/anktiva): Glioblastoma, Long COVID
- [Cd19 t-hank- iv administration](https://sec-api.dev/pdufa/cd19-t-hank-iv-administration): Relapsed B-Cell Non Hodgkin Lymphoma
- [ANKTIVA (inbakicept)](https://sec-api.dev/pdufa/inbakicept): bcg-naïve nmibc, bgc-unresponsive nonmuscle invasive bladder cancer
- [N-803](https://sec-api.dev/pdufa/n-803): NSCLC Stage IV, Platinum-resistant Ovarian Cancer, Relapsed B-Cell Non-Hodgkin Lymphoma, Pancreatic Cancer
- [N-803 and bcg](https://sec-api.dev/pdufa/n-803-and-bcg): Non-muscle Invasive Bladder Cancer (NMIBC)
- [N-803 (il-15 superagonist)](https://sec-api.dev/pdufa/n-803-il-15-superagonist): Long COVID
- [N-803 + pembrolizumab](https://sec-api.dev/pdufa/n-803-pembrolizumab): Non-Small Cell Lung Cancer
- [Nai + pembrolizumab](https://sec-api.dev/pdufa/nai-pembrolizumab): Non Small Cell Lung Cancer
- [Nogapendekin alfa inbakicept (nai)](https://sec-api.dev/pdufa/nogapendekin-alfa-inbakicept-nai): Sepsis

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/ibrx/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "IBRX catalysts: ImmunityBio, Inc. PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/ibrx/catalysts

```bibtex
@misc{secapidev_companies_ibrx_catalysts_20261116,
  title        = {IBRX catalysts: ImmunityBio, Inc. PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/ibrx/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_ibrx_catalysts_20261116","title":"IBRX catalysts: ImmunityBio, Inc. PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/ibrx/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
